Truman Rosemarie, Locke Cody J
The Center for Advancing Innovation, INC., Bethesda, MD USA.
Cancer Nanotechnol. 2016;7:4. doi: 10.1186/s12645-016-0017-6. Epub 2016 Jun 9.
On March 4th, 2016, Springer's C office promoted the launch of the ( ). This innovation-development model is a partnership among our company, the Center for Advancing Innovation (CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes at the National Institutes of Health (NIH). "crowdsources" talent from around the world to launch startups with near-term, commercially viable cancer nanotechnology inventions, which were developed by the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Biomedical Imaging and Bioengineering (NIBIB). Crowdsourcing is a process in which one uses the internet to engage a large group of people in an activity, such as . For this initiative, CAI engaged universities, industry professionals, foundations, investors, relevant media outlets, seasoned entrepreneurs, and life sciences membership organizations to request that they participate in the challenge. From this outreach, fifty-six key thought leaders have enrolled in as judges, mentors, and/or advisors to challenge teams (http://www.nscsquared.org/judges.html). Along with crowdsourcing talent to bolt startups around NIH inventions, will also catalyze the launch of companies around "third-party" cancer nanotechnology inventions, which were conceived and developed outside of the NIH. Twenty-eight robust teams were accepted to the challenge on March 14th, 2016.
2016年3月4日，施普林格公司的C办公室推动了（ ）的启动。这种创新发展模式是我们公司、创新推进中心（CAI）、阿斯利康全球生物制品部门美达免疫公司以及美国国立卫生研究院（NIH）的多个研究所之间的合作关系。“众包”来自世界各地的人才，利用美国国立癌症研究所（NCI）、国立心肺血液研究所（NHLBI）和国立生物医学成像与生物工程研究所（NIBIB）研发的具有近期商业可行性的癌症纳米技术发明来创办初创企业。众包是一种利用互联网让大量人群参与某项活动的过程，比如（此处原文缺失具体活动内容）。对于这项倡议，CAI邀请了大学、行业专业人士、基金会、投资者、相关媒体机构、经验丰富的企业家以及生命科学会员组织，请求他们参与这项挑战。通过此次拓展，56位关键思想领袖已报名成为（此处原文缺失具体项目名称）的评委、导师和/或顾问，为参赛团队提供挑战指导（http://www.nscsquared.org/judges.html）。除了众包人才围绕NIH的发明创办初创企业外，（此处原文缺失具体项目名称）还将推动围绕“第三方”癌症纳米技术发明创办公司，这些发明是在NIH之外构思和研发的。2016年3月14日，28支实力强劲的团队被接受参加这项挑战。
